乳腺癌雌激素受体、孕激素受体、人类表皮生长因子受体-2及血清肿瘤标志物水平与骨转移的关系*

Study on ER, PR, HER-2 expression with serum tumor makers and bone metastasis in breast cancer*

摘要:

目的 探讨乳腺癌雌激素受体（ER）、孕激素受体（PR）、人表皮生长因子受体-2（HER2）的表达及血清肿瘤标志物水平与骨转移的关系。方法 收集从2013年1月—2015年10月锦州医科大学附属第一医院经病理确诊为乳腺癌并经全身骨显像结合临床表现及其他影像学方法确诊的骨转移患者52例和无骨转移患者111例。对患者进行血清肿瘤标志物癌胚抗原（CEA）、糖类抗原（CA）153的测定，并对乳腺癌标本进行ER、PR、HER2的免疫组织化学检测。结果 不同分子分型乳腺癌患者骨转移与无骨转移差异有统计学意义（P?<0.05）。单发骨转移、多发骨转移及无转移组ER、PR、HER2差异有统计学意义（P?<0.05）。乳腺癌患者单发骨转移及多发骨转移组血清CEA、CA153水平均高于无骨转移组（P?<0.05）。结论 乳腺癌骨转移与无骨转移患者间分子分型、ER、PR和HER2表达水平及血清CEA、CA153水平有差异，骨转移越严重，血清CEA、CA153水平越高。

关键词:乳腺肿瘤;骨转移;肿瘤标志物;免疫组织化学

Abstract:

Objective To investigate the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2) and serum tumor markers as well as bone metastasis in breast cancer patients. Methods Fifty two patients with bone metastasis and 111 patients without bone metastasis who were diagnosed breast cancer by pathology and were confirmed by whole body bone imaging method and others imaging methods, and clinical manifestation were collected from Jan.2013 to Oct. 2015 in our hospital. Serum tumor marker carcinoembryonic antigen (CEA), carbohydrate antigen 153 (CA153) were measured in these patients, and ER, PR, HER2 of immunohistochemical test were performed on lesions of breast cancer resected. Results The bone metastasis of breast cancer patients with different subtypes of genes were significantly in statistical (P?

Key words:breast neoplasms; bone metastases; biomarkers, tumor; immunohistochemistry